StemCell Therapy

ALBANY, N.Y., June 7, 2022 /PRNewswire/ -- TMR study for eye care surgical devices market projections estimates the said market to peg a CAGR of 5.5% for the forecast period from 2022 to 2031. Demand for eye care surgical devices has been rising significantly due to increase in incidence of ophthalmic disorders such as cataract, glaucoma, and other vision-related disorders that are leading causes of blindness and visual impairment. Eye care surgical devices range include both non-invasive and invasive diagnostic devices and instruments such as contact lenses, glaucoma stents, and intraocular lenses.

Eye care surgical devices market outlook is promising with the availability of technologically advanced cataract surgery equipment resulting in improved clinical outcomes. Emerging trend of advancements in cataract surgery equipment has led to improved safety and effectiveness of common procedures.

In general, for clinical purposes, ophthalmology and its subspecialties are at the forefront embracing rapid technological advancements. For example, apodization has resulted in intraocular lens technology to progress from refractive to diffractive to result in fewer and less severe visual side effects.

Request Brochure of Eye Care Surgical Devices Market Research Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=49896

Eye Care Surgical Devices Market Key Findings of the Report

Request for Analysis of COVID-19 Impact on Eye Care Surgical Devices Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=49896

Eye Care Surgical Devices Market Growth Drivers

Get Exclusive PDF Sample Copy of Eye Care Surgical Devices Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=49896

Eye Care Surgical Devices Market Key Players

Some of the key players operating in the eye care surgical devices market are;

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=49896

The eye care surgical devices market is segmented as follows;

Eye Care Surgical Devices Market, by Product Type

Eye Care Surgical Devices Market, by End-user

Eye Care Surgical Devices Market, by Application

Eye Care Surgical Devices Market, by Region

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated withLatest Healthcare Industry Research Reportsby Transparency Market Research:

Ophthalmic Surgical Devices and Therapeutics Market: Increase in prevalence and incidence rates of eye-related disorders, high unmet needs in patients with ocular diseases, increased geriatric population, and raised awareness about eye diseases in developing countries are expected to boost the ophthalmic surgical devices and therapeutics market during the forecast period.

Vascular Stents Market: Rise in prevalence of cardiovascular diseases and increase in demand for minimally invasive surgeries are anticipated to drive the global vascular stents market from 2019 to 2027. The global vascular stents market is responding positively to new and innovative coronary stents, with increasing uptake of technologically advanced coronary stents.

Dry Eye Disease Market: The growing prevalence of these diseases has urged many researchers and developers to discover good treatment options, which has eventually accelerated the growth prospects of the dry eye disease market.

Dry Eye Disease Diagnostic Devices Market: Surge in the geriatric population and rise in prevalence & incidence rates of dry eye disease in the U.S. are projected to drive the dry eye disease diagnostic devices market.

Dry Eye Disease Treatment Market: Rise in reported cases of dry eye disease, increase in the number of surgical procedures such as LASIK surgery, adverse effects of rising pollution levels, advances in treatment of dry eye, and introduction of new therapies are projected to drive the global dry eye disease treatment market.

About Us

Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update -https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact Us:

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:http://www.transparencymarketresearch.comBlog:https://tmrblog.comEmail:%5Bemailprotected%5D

SOURCE Transparency Market Research

Follow this link:
Valuation of Eye Care Surgical Devices Market Estimated at US$ 10.7 Bn by 2031, TMR Report - PR Newswire

(June 6, 2022 / Jewish Journal) All of life is a footnote to love and death. These two poles of existence overshadow everything else; love creates life and death takes it away, filling our lives with joy and sorrow in unending succession.

It is easiest to consider love and death separately, as two very different chapters of life; and emotionally, they are worlds apart. Halachah is a reflection of this instinct, treating mourning and celebration as irreconcilable opposites. Mourners dont attend celebrations and parties, and the joy of the holidays terminates shiva. The heart cannot accommodate both joy and grief at the same time, because both love and death inspire intense, all-encompassing emotions.

Love is intoxicating. Shir Hashirim, the Song of Songs, portrays the exceptional power of love through a depiction of couples who are lovesick and unable to act rationally. And this reality repeats itself over and over in history. When Jacob falls in love with Rachel, he dramatically overpays for her dowry, offering to work seven full years for her hand. Even so, Jacob imagines that he is the one who is getting a bargain because he is so much in love with Rachel; the seven years seem like a small price to pay for Rachels hand in marriage. Jacob is blinded by love.

William Blake captures this mindless blindness in a short poem: Love to faults is always blind, Always is to joy inclind, Lawless, wingd and unconfind, And breaks all chains from every mind. Love hatches remarkable dreams that fly in every direction; with love nothing seems impossible. Lovers are oblivious to reality and live in their own two-person universe, just like Adam and Eve in the Garden of Eden.

Death brings a blindness of its own. When King Solomon writes the book of Kohelet, Ecclesiastes, he begins with a lament about the pointlessness of life. As Rashi puts it, The author of Kohelet issues a complaint against the seven days of creation, that [the world] is all a vanity of vanities. Death, the question without an answer, confounds him. What point does life have, Kohelet asks, if the righteous man meets the same end as the wicked, and the wise man has the same fate as an animal? (The bitter, skeptical tone of Kohelet seems out of place in the Tanakh. I sometimes wonder if the purpose of Kohelet is to expose us to our own bitterness and cynicism, to recognize that hope will disintegrate without faith.)

Subscribe to The JNS Daily Syndicateby email and never missour top stories

Whenever one looks death in the eye, optimism and joy quickly evaporate. Franz Rosenzweig notes how life stands in the shadow of death, and all that is mortal lives in fear of death each newly born waits with fear and trembling for the day of its passage into the dark every new birth multiplies the fear for it multiplies that which is mortal. When one enters the realm of death, a cold cynicism descends, choking off any experience of joy.

The poetry of Shir Hashirim and the acerbic philosophy of Kohelet each deserve their own book. They faithfully explore the experiences of passion and despair. And because the emotions of joy and grief are opposites, we assume that the experiences of love and death are utterly incompatible. But they are not.

A third biblical book, the Book of Ruth, brings death and love together. In it, a family moves from Israel to Moab, where the sons take Moabite wives for themselves. In short succession, this family is devastated by death with the father and his two sons passing away at a young age. Alone and impoverished, one of the sons wives, Ruth, returns with her beloved mother-in-law, Naomi, to Israel, abandoning her homeland to remain with her. Ruth persists despite discrimination and desperation, and insists that she will perpetuate her husbands familys legacy; and in the end, she does just that. She marries a relative of her husbands, Boaz, and the family continues: Their great-grandson is King David.

The Book of Ruth is not just a book of love and death; it is a book about a different type of love, love in the shadow of death. After the familys tragedies, Naomi succumbs to cynicism; she even suggests she should rename herself bitter. Ruth refuses this path; she battles with the angel of death. Ruth teaches us how to pursue redemption in the valley of the shadow of death.

The Hebrew word for redemption, gaal, appears multiple times in the book of Ruth because it is a book about redemptions, both large and small. By remarrying and bringing grandchildren to Naomi, Ruth redeems and rebuilds a once broken family. And later, her descendant King David will be the very symbol of Messianic redemption and bring redemption to the nation as a whole.

Ordinarily, death erases life and destroys all that love has built. But in redemption, it is love that gets the final word, staying one step ahead in a cosmic wrestling match. It is when you continue to love after a tragedy, when you courageously pour your broken heart into rebuilding a broken world, you have taken the first steps on the road to redemption.

The very foundation of Jewish history is redemption; it is the story of a people who, despite having every reason to be bitter and cynical, continued to rebuild and repair. This has never been more evident than in the past century. Crushed by the Holocaust, it would have made sense for the Jews to give up. Instead, following Ruths example, they built the State of Israel, a modern-day miracle of redemption.

Last week I joined the Ramaz Upper School mission to Israel, together with nearly 500 students and teachers. Israel is filled with stories of redemption, both large and small. At Tel-a-Sakithe sight of one of the fiercest battles of the Yom Kippur Warwe were told about the heroism of the soldiers who fought there. Three tanks, under the command of Yoav Yakir, held off hundreds of Syrian tanks for nearly two days, giving the army precious time to reinforce their defenses on the Golan Heights. Even after it became clear that they were no longer able to hold off the Syrians, Yoav chose to fight as long as possible and fell in battle.

After the war, a member of Yoavs unit, Yitzchak Nagarker, had a baby boy. (Yitzchak is a war hero in his own right, with his own incredible story of courage.) At the brit, Yitzchak invited Yoavs father to be the sandak and named his first born Yoav, in honor of his fallen comrade. Love is as strong as death, and is the very instrument of redemption, and Yoavs legacy continues to live on in Yitzchaks son.

Our mission prayed at the Kotel on Friday night, just a day before Yom Yerushalayim, Jerusalem Day. Through hundreds of years of exile, the passion the Jewish people had for Jerusalem never wavered. They continued to dream of this place, to declare Lshanah habaah byerushalayim,next year in Jerusalem. And on June 7, 1967, for the first time in 1900 years, that dream came true. An Israeli flag was raised over the Kotel. With tears in their eyes, the exiles had returned to Zion. The Kotel is the ultimate monument to redemption, and its stones whisper, Am Yisrael Chai, the Jewish people live on.

After services on Friday night, the Ramaz students gathered in the plaza, waiting to walk together as a group to Shabbat dinner. Then something remarkable happened. They gathered together in one large circle, singing Jewish songs for half an hour; other visitors came over to watch this moment of inspiration. At that moment, the students were making Ruths legacy their own. They were singing the song of redemption, continuing an undying love story that has lasted for thousands of years.

Rabbi Chaim Steinmetz is the senior rabbi of Congregation Kehilath Jeshurun in New York.

This article was originally published by theJewish Journal.

Visit link:
Love in the shadow of death: The story of Ruth - JNS.org

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

BROSSARD, Quebec, June 07, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (DIAGNOS, the Corporation or we) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the deployment of its Age-Related Macular Degeneration detection application into the optometry clinics of IRIS The Visual Group.

It is with great pleasure that DIAGNOS is announcing the deployment of its Age-Related Macular Degeneration (AMD) detection application into the optometry clinics of IRIS The Visual Group (IRIS). With over 1,250 patients having received this new test already, we can see that the demand is great for this application in clinical optometry and optical retail. This deployment of this application represents an important milestone in the Artificial Intelligence Technology Implementation Program announced in June 2021 by the two groups.

We are thrilled by the addition of the AMD detection application into our portfolio as it further expands the value our company offers to eyecare providers, an important segment of our market expansion strategy. saysMr. Yves-Stphane Couture, Vice-President of DIAGNOS. The quality of the relationship we developed with IRIS throughout this project and the constant spirit of collaboration and desire to improve patient outcomes shared by our respective organizations have been decisive in the development of this new tool, it positively and directly contributed to the deployment we are doing today.

AMD is a leading cause of visual deterioration and legal blindness in people over 60 years of age. The loss of central vision and high-resolution visual acuity from untreated AMD can lead to irreversible loss of reading, depression, reduced facial recognition ability, and disqualification from driving. Regular screening for eye diseases is of the utmost importance to enable early detection of eye disease and prevent major alterations in quality of life from occurring.

The deployment of this new application in our clinics is perfectly aligned with IRIS desire to be at the forefront of technological advances in its clinical optometry and optical retail operations. We strive to provide our customers with the most effective cutting-edge technologies, with tools that enhance the healthcare experience we provide and improve clinical outcomes. Artificial Intelligence solutions like that of DIAGNOS raise the bar in terms of quality of care and perfectly illustrate of the benefits of our collaboration with this company. said Dr. Jahel St-Jacques, Optometrist and Vice-President of IRIS.

DIAGNOS is currently putting the finishing touches on several Artificial Intelligence Deep Learning algorithms focused on disease detection and aimed to improve clinical operations and patient outcomes. The launch of the AMD detection application is the first in a series of important launches planned soon, that will ensure the success and sustainability of the organization.

About IRISIRIS was founded in 1990 in Quebec. Since that time, IRIS has developed into the largest network of optometrists, opticians and ophthalmologists operating under the same banner across Canada. The companys locations combine clinical optometry and optical retail to provide a unique concept and a commitment to offering top quality products and services in the field of eyecare.

Additional information is available at http://www.iris.ca

About DIAGNOSDIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARAs image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available atwww.DIAGNOS.com andwww.sedar.com

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Here is the original post:
DIAGNOS Announces the Deployment of its Age-Related Macular Degeneration Detection Application Into the Optometry Clinics of IRIS, The Visual Group -...

HOUSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing multiple first-in-class and best-in-class approaches that enhance regulatory T cell (Treg) function, today announced that it has raised approximately $10.3 million from institutional and accredited investors. The financing brings the total funding to date to over $20 million.

Originally posted here:
Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T Cell Therapeutics

New York, NY, and Tel Aviv, ISRAEL, June 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 28 update from an ongoing case study by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary supplement, in a patient who originally contracted COVID in December 2021 and experienced symptoms of Long COVID, including erectile dysfunction.

Visit link:
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction

Basel, June 7, 2022 — Novartis today announced longer-term follow-up data from the Phase III ASCEMBL trial for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors (TKIs), presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. In this analysis, the proportion of patients in the Scemblix® (asciminib) arm (n=157) who achieved a major molecular response (MMR) at 96 weeks was more than double that in the Bosulif® (bosutinib) arm (n=76) (37.6% vs. 15.8% [P=.001]), substantially increasing from previous analyses1,2. Additionally, the probability of maintaining MMR for at least 72 weeks for patients treated with Scemblix was 96.7% (95% CI, 87.4%–99.2%), reflecting long-term durability of efficacy1.

Read more:
Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic...

Saint-Herblain (France), June 7, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will present on its single-shot chikungunya vaccine candidate VLA1553 on June 9, 2022 at the 8th Northern European Conference on Travel Medicine (NECTM8) in Rotterdam.

Read more:
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8

PRESS RELEASE

Continue reading here:
AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the...

CRANBURY, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that preliminary results from the ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors harboring a p53 Y220C mutation demonstrated anti-tumor efficacy across multiple tumor types with an acceptable safety profile. PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation in solid tumors.

Read more here:
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C...

Leuven, BELGIUM, Boston, MA, US – JUNE 7, 2022 – Oxurion NV (Euronext Brussels: OXUR), a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies in patients with retinal disorders including diabetic macular edema, today delivered a preclinical presentation evaluating the pharmacokinetic properties of THR-149 at KININ2022, held in Annecy, France, June 5-8, 2022.

Read the original here:
Oxurion Announces Preclinical Presentation on THR-149 at KININ2022

New Super-Premium Natural Pet Food Brand from Better Choice Company Targets Millennial and Gen Z Pet Parents New Super-Premium Natural Pet Food Brand from Better Choice Company Targets Millennial and Gen Z Pet Parents

Read this article:
Halo Pet Launches Multi-Million Dollar Marketing Campaign to Celebrate the World's Best Kids: Your Pet

TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be presenting and exhibiting at Outsourcing in Clinical Trials: Medical Devices USA 2022, June 8-9 in Irvine, CA.

Go here to read the rest:
Axiom Presenting “Safety First: How Integrated Clinical Platforms Offer a Critical Advantage in Managing the Various Points to Control Safety” at...

Daix (France), Long Island City (New York, United States), June 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that it will join the Euronext Tech Leaders initiative, a new Euronext segment comprised of more than 100 high-growth and leading Tech companies across Europe.

View original post here:
Inventiva joins the Euronext Tech Leaders segment

BOSTON and LOUISVILLE, Ky., June 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented additional data and analyses from its Phase 2 trial of FCR001 and other studies of its Facilitated Allo-HSCT Therapy platform at the 2022 American Transplant Congress (ATC).

Visit link:
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

Thursday, June 16th @ 10:30 a.m. ET Thursday, June 16th @ 10:30 a.m. ET

Excerpt from:
Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference at 4:00 p.m. PT on Tuesday, June 14, 2022. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

See more here:
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14 at 10:40am PT.

Read more:
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

SAN FRANCISCO, June 07, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. Eastern Time in New York City, NY.

Go here to read the rest:
Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET

Montrouge, France, June 7, 2022

Read more here:
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Original post:
Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic...